search
Back to results

A Phase I of SS109 in Hemophilia A or and B With Inhibitors

Primary Purpose

Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Factor VII Deficiency

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
SS109
Sponsored by
Jiangsu Gensciences lnc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hemophilia A With Inhibitor

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria: Age was 18 to 65 years old,when signing the informed consent form, male; Clinical diagnosis of hemophilia A or B (previous or screening period FⅧ activity level≤ 1% or FⅨ activity level≤ 2%), and there is one of the following conditions: FⅧ or FⅨ inhibitor level ≥ 5Bu/mL during screening period; During the screening period, the level of FⅧ and FⅨ inhibitors was less than 5 Bu/mL and more than 0.6 Bu/mL, but had a high response to factor Ⅷ or IX injection (such as, the patient had a positive history of FⅧ/FⅨ inhibitors, and then the inhibitor level is ≥ 5Bu/mL, after the second infusion of FⅧ/FⅨ); No active bleeding symptoms before the first injection; Patients can comply with the requirements of the protocol and be willing to complete the study as planned and provide biological samples for test; Be able to understand the procedures and methods of this clinical trial. The patient voluntarily participates and signs by himself or by the impartial witness Exclusion Criteria: Patients with known history of hypersensitivity to the investigational drug preparation and any of its components; There was hypersensitivity or anaphylaxis after FⅦ or IgG2 injection treatment in the past; Patients with FⅦ inhibitor positive or with FⅦ inhibitor positive history in screening period; Severe anemia (hemoglobin < 60g/L); Platelet count < 100 × 109/L; Patients with abnormal liver and kidney functions: alanine aminotransferase (ALT) or aspartate aminotransferase (AST)≥ 2.5 times the upper limit of normal value (ULN), or total bilirubin ≥ 1.5 times ULN; or blood creatinine (Cr) ≥ 1.5 times; One or more tests are positive, such as HBsAg, HCV antibody, anti-human immunity for HIV antibody and anti-treponema pallidum specific antibody (TPHA); Except for hemophilia A or B, the coagulation indexes of any other bleeding disease or other diseases are obviously different(such as platelet disease, vitamin K deficiency, etc.); History or symptoms of any previous arterial or venous thromboembolism event (such as atherosclerosis, myocardial infarction, ischemic stroke, transient ischemic attack, deep vein thrombosis or pulmonary hypertension, pulmonary embolism), or patients with history of disseminated intravascular coagulation (DIC); Suffered from serious heart disease, such as unstable angina, congestive heart failure (New York Heart Association, ≥ Grade III), severe arrhythmia (QTc interval>450ms, corrected by Fridericia formula), hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 95 mmHg) not controlled by treatment; Receive any product containing FⅦ or FⅦa (plasma derived or recombinate) within 48 hours before the first injection; Receive any product containing FⅧ (plasma derived or recombinate) within 72 hours before the first injection; or receive any product containing FIX (plasma derived or recombinate) within 96 hours before administration; Patients have used any anticoagulant, anti-fibrinol solvent, chemical, biological products or traditional Chinese medicine that affect platelet function within one week before the first injection or need to use any anticoagulant, anti-fibrinol solvent during PK/PD period, including non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin; Patients have received immunomodulator (such as gamma globulin α- Interferon and prednisone>10mg/d [and>7 days] or similar drugs, except antiretroviral drugs); Patients who received whole blood or plasma treatment within 2 weeks before the first injection; Patients who have received vaccines within 4 weeks or planned to be vaccinated during the trial before the first injection; Major surgery (such as orthopedic surgery and abdominal surgery) was performed within 1 month before the first injection, or planned to undergo surgery during the study; Patients who have been selected into other clinical trials within 1 month before the first injection; Patients with a history of drug abuse or alcohol abuse (alcohol abuse standard: male with a long-term alcohol consumption history of more than 5 years, equivalent to alcohol ≥ 40g/d, ≥ 20g/d for women, or a history of heavy drinking within 2 weeks, with the equivalent alcohol volume > 80g/d. Patients suffering from mental illness or obvious mental disorder, or incapacity and lack of cognition caused by other reasons A birth plan or sperm donation plan from the study to 3 months after the study, or patients are unwilling to take contraceptive measures (such as condoms, diaphragms, intrauterine devices, etc.); A disease with clinical significance or other reasons that the researcher thinks patients are not suitable for participating in this clinical trial (if patients cannot benefit from clinical trials); The investigator considers patients with poor compliance, and patients will be impossible to evaluate the efficacy or accomplish the course of treatment and follow-up.

Sites / Locations

  • Anhui Provincial Hospital
  • Henan Provincial Cancer Hospital
  • Xiangya Hospital, Central South University
  • Affiliated Hospital of Xuzhou Medical University
  • Jiangxi Provincial People's Hospital
  • The First Affiliated Hospital of Shandong First Medical University
  • The Second Hospital of Shanxi Medical University
  • Xi'an Central Hospital
  • Hematology Hospital, Chinese Academy of Medical Sciences
  • The Second Affiliated Hospital of Kunming Medical University

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Dose cohorts

Arm Description

Dose cohorts were designed to evaluate the safety, immunogenicity and PK/PD.

Outcomes

Primary Outcome Measures

The incidence of adverse event/serious adverse event/specical interest adverse event(AE/SAE/AESI)
AE/SAE/AESI is any untoward clinical signs, symptoms or outcomes
Number of patients with positive FVII inhibitor, anti- drug antibody (ADA)
Number of patients with positive FVII inhibitor, anti drug antibody (ADA)

Secondary Outcome Measures

Half-life
Cmax
Maximum concentration
Tmax
Time to reach maximum concentration
AUC0-last
Area under the curve from 0 to last
AUC0-72
Area under the curve from 0 to 72 hour
AUC0-∞
Area under the curve from 0 to ∞
CL
Clearance
Vd
Volume of distribution
MRT
Mean residence time
IR
Incremental recovery rate

Full Information

First Posted
November 29, 2022
Last Updated
August 21, 2023
Sponsor
Jiangsu Gensciences lnc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05651061
Brief Title
A Phase I of SS109 in Hemophilia A or and B With Inhibitors
Official Title
To Evaluate the Safety, PK/PD and Immunogenicity of SS109 in Hemophilia Patients With Blood Coagulation Factor Ⅷ or Ⅸ Inhibitors After Single Administration, Open Label, Dose Escalation, and Multicenter Phase I Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
December 14, 2022 (Actual)
Primary Completion Date
March 31, 2023 (Actual)
Study Completion Date
August 15, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jiangsu Gensciences lnc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This phase I study aims to evaluate the safety, PK/PD and immunogenicity of SS109 in hemophilia A or and B with inhibitors. Twenty -seven patients are enrolled in study, and divided into five dose cohorts, from 30μg/kg to 360μg/kg. Dose 1 cohort enrolls three patients, each other dose cohorts enroll six patients. All patients included in the study will continue to be followed up until 28 days after SS109 administration.
Detailed Description
This study is an open label, dose escalation, multicenter clinical trial. The study sets up a science review committee to assess the dose escalation. Serial blood samples for PK/PD analysis will be taken up to 72 hours after SS109 injection. Patients safety will be routinely monitored throughout the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Factor VII Deficiency

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
27 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dose cohorts
Arm Type
Experimental
Arm Description
Dose cohorts were designed to evaluate the safety, immunogenicity and PK/PD.
Intervention Type
Biological
Intervention Name(s)
SS109
Intervention Description
27 patients are enrolled in cohorts ,and will continue to be followed up until 28 days after SS109 administration for evaluating safety, PK/PD and immunogenicity.
Primary Outcome Measure Information:
Title
The incidence of adverse event/serious adverse event/specical interest adverse event(AE/SAE/AESI)
Description
AE/SAE/AESI is any untoward clinical signs, symptoms or outcomes
Time Frame
Up to 28 days after SS109 injected
Title
Number of patients with positive FVII inhibitor, anti- drug antibody (ADA)
Description
Number of patients with positive FVII inhibitor, anti drug antibody (ADA)
Time Frame
Up to 28 days after SS109 injected
Secondary Outcome Measure Information:
Title
Description
Half-life
Time Frame
Up to 72 hours after SS109 injected
Title
Cmax
Description
Maximum concentration
Time Frame
Up to 72 hours after SS109 injected
Title
Tmax
Description
Time to reach maximum concentration
Time Frame
Up to 72 hours after SS109 injected
Title
AUC0-last
Description
Area under the curve from 0 to last
Time Frame
Up to 72 hours after SS109 injected
Title
AUC0-72
Description
Area under the curve from 0 to 72 hour
Time Frame
Up to 72 hours after SS109 injected
Title
AUC0-∞
Description
Area under the curve from 0 to ∞
Time Frame
Up to 72 hours after SS109 injected
Title
CL
Description
Clearance
Time Frame
Up to 72 hours after SS109 injected
Title
Vd
Description
Volume of distribution
Time Frame
Up to 72 hours after SS109 injected
Title
MRT
Description
Mean residence time
Time Frame
Up to 72 hours after SS109 injected
Title
IR
Description
Incremental recovery rate
Time Frame
Up to 72 hours after SS109 injected
Other Pre-specified Outcome Measures:
Title
PT
Description
Prothrombin time
Time Frame
Up to 72 hours after SS109 injected
Title
aPTT
Description
activated partial thromboplastin time
Time Frame
Up to 72 hours after SS109 injected
Title
TGA
Description
thrombin generation test
Time Frame
Up to 72 hours after SS109 injected
Title
TAT
Description
thrombin antithrombin complex
Time Frame
Up to 72 hours after SS109 injected

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age was 18 to 65 years old,when signing the informed consent form, male; Clinical diagnosis of hemophilia A or B (previous or screening period FⅧ activity level≤ 1% or FⅨ activity level≤ 2%), and there is one of the following conditions: FⅧ or FⅨ inhibitor level ≥ 5Bu/mL during screening period; During the screening period, the level of FⅧ and FⅨ inhibitors was less than 5 Bu/mL and more than 0.6 Bu/mL, but had a high response to factor Ⅷ or IX injection (such as, the patient had a positive history of FⅧ/FⅨ inhibitors, and then the inhibitor level is ≥ 5Bu/mL, after the second infusion of FⅧ/FⅨ); No active bleeding symptoms before the first injection; Patients can comply with the requirements of the protocol and be willing to complete the study as planned and provide biological samples for test; Be able to understand the procedures and methods of this clinical trial. The patient voluntarily participates and signs by himself or by the impartial witness Exclusion Criteria: Patients with known history of hypersensitivity to the investigational drug preparation and any of its components; There was hypersensitivity or anaphylaxis after FⅦ or IgG2 injection treatment in the past; Patients with FⅦ inhibitor positive or with FⅦ inhibitor positive history in screening period; Severe anemia (hemoglobin < 60g/L); Platelet count < 100 × 109/L; Patients with abnormal liver and kidney functions: alanine aminotransferase (ALT) or aspartate aminotransferase (AST)≥ 2.5 times the upper limit of normal value (ULN), or total bilirubin ≥ 1.5 times ULN; or blood creatinine (Cr) ≥ 1.5 times; One or more tests are positive, such as HBsAg, HCV antibody, anti-human immunity for HIV antibody and anti-treponema pallidum specific antibody (TPHA); Except for hemophilia A or B, the coagulation indexes of any other bleeding disease or other diseases are obviously different(such as platelet disease, vitamin K deficiency, etc.); History or symptoms of any previous arterial or venous thromboembolism event (such as atherosclerosis, myocardial infarction, ischemic stroke, transient ischemic attack, deep vein thrombosis or pulmonary hypertension, pulmonary embolism), or patients with history of disseminated intravascular coagulation (DIC); Suffered from serious heart disease, such as unstable angina, congestive heart failure (New York Heart Association, ≥ Grade III), severe arrhythmia (QTc interval>450ms, corrected by Fridericia formula), hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 95 mmHg) not controlled by treatment; Receive any product containing FⅦ or FⅦa (plasma derived or recombinate) within 48 hours before the first injection; Receive any product containing FⅧ (plasma derived or recombinate) within 72 hours before the first injection; or receive any product containing FIX (plasma derived or recombinate) within 96 hours before administration; Patients have used any anticoagulant, anti-fibrinol solvent, chemical, biological products or traditional Chinese medicine that affect platelet function within one week before the first injection or need to use any anticoagulant, anti-fibrinol solvent during PK/PD period, including non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin; Patients have received immunomodulator (such as gamma globulin α- Interferon and prednisone>10mg/d [and>7 days] or similar drugs, except antiretroviral drugs); Patients who received whole blood or plasma treatment within 2 weeks before the first injection; Patients who have received vaccines within 4 weeks or planned to be vaccinated during the trial before the first injection; Major surgery (such as orthopedic surgery and abdominal surgery) was performed within 1 month before the first injection, or planned to undergo surgery during the study; Patients who have been selected into other clinical trials within 1 month before the first injection; Patients with a history of drug abuse or alcohol abuse (alcohol abuse standard: male with a long-term alcohol consumption history of more than 5 years, equivalent to alcohol ≥ 40g/d, ≥ 20g/d for women, or a history of heavy drinking within 2 weeks, with the equivalent alcohol volume > 80g/d. Patients suffering from mental illness or obvious mental disorder, or incapacity and lack of cognition caused by other reasons A birth plan or sperm donation plan from the study to 3 months after the study, or patients are unwilling to take contraceptive measures (such as condoms, diaphragms, intrauterine devices, etc.); A disease with clinical significance or other reasons that the researcher thinks patients are not suitable for participating in this clinical trial (if patients cannot benefit from clinical trials); The investigator considers patients with poor compliance, and patients will be impossible to evaluate the efficacy or accomplish the course of treatment and follow-up.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Renchi Yang
Organizational Affiliation
Hematology Hospital, Chinese Academy of Medical Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Anhui Provincial Hospital
City
Hefei
State/Province
Anhui
Country
China
Facility Name
Henan Provincial Cancer Hospital
City
Zhengzhou
State/Province
Henan
Country
China
Facility Name
Xiangya Hospital, Central South University
City
Changsha
State/Province
Hunan
Country
China
Facility Name
Affiliated Hospital of Xuzhou Medical University
City
Xuzhou
State/Province
Jiangsu
Country
China
Facility Name
Jiangxi Provincial People's Hospital
City
Nanchang
State/Province
Jiangxi
Country
China
Facility Name
The First Affiliated Hospital of Shandong First Medical University
City
Jinan
State/Province
Shandong
Country
China
Facility Name
The Second Hospital of Shanxi Medical University
City
Taiyuan
State/Province
Shanxi
Country
China
Facility Name
Xi'an Central Hospital
City
Xi'an
State/Province
Shanxi
Country
China
Facility Name
Hematology Hospital, Chinese Academy of Medical Sciences
City
Tianjin
State/Province
Tianjin
Country
China
Facility Name
The Second Affiliated Hospital of Kunming Medical University
City
Kunming
State/Province
Yunnan
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Phase I of SS109 in Hemophilia A or and B With Inhibitors

We'll reach out to this number within 24 hrs